Investors might want to bet on Dynavax Technologies (DVAX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...

Dynavax Technologies (DVAX) closed the last trading session at $13.01, gaining 24.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24.50 indicates an 88.3% upside potential.The average comprises four short-term price targets ranging from a low of $15 to a high of $29, with a standard deviation of $6.61. While the lowest estimate indicates an increase of 15.3% from the current pr ...

EMERYVILLE, Calif., Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs & Co. LLC to repurchase $100 million of the Company's common stock. Dynavax executed the ASR as part of the $200 million share repurchase program authorized by its Board of Directors in ...

Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Jon Miller - Evercore Ernie Rodriguez - TD Cowen Paul Choi - Goldman Sachs Roy Buchanan - Citizen ...

| --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | Q3 2024 Financial Results | | | | | | Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases | | | | | | | | | | | | November 2024 Nasdaq: DVAX | | | | | Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward-l ...

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.06 per share when it actually produced earnings of $0.08, delivering a surprise of 33.33%.Over the last four qu ...

Table of Contents Title of each class: Trading symbol(s): Name of each exchange on which registered: Common Stock, $0.001 par value DVAX Nasdaq Global Select Market Preferred Share Purchase Rights N/A Nasdaq Global Select Market Large accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ Form 10-Q __________________ ...

Exhibit 99.1 Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates • HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-overyear growth • Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share • Expect positive net income in 2024, achieving full year profitability • Strengthened cash position to $764 million in Q3'24 • $200 million sha ...

HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share Expect positive net income in 2024, achieving full year profitability Strengthened cash position to $764 million in Q3'24  $200 million share repurchase program announced as part of balanced capital allocation strategy Conference call today ...

EMERYVILLE, Calif., Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced its Board of Directors has authorized the repurchase of up to $200 million of the Company's common stock. The share repurchase program does not have an expiration date and Dynavax currently expects that purchases will be executed within a period of up to one year."Dynavax maintains a disciplined and ...